Michael Untch
0000-0002-1233-1267
Publication & Citation Trends
Most Cited Works
Publications
1,373 total
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Cited by 759
OpenAlex
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Cited by 2,080
OpenAlex
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial PDF
Cited by 1,022
OpenAlex
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis PDF
Cited by 4,623
OpenAlex
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers PDF
Cited by 1,021
OpenAlex
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Cited by 1,020
OpenAlex
Research Topics
Breast Cancer Treatment Studies
(680)
HER2/EGFR in Cancer Research
(459)
Cancer Treatment and Pharmacology
(350)
Advanced Breast Cancer Therapies
(313)
Cancer Genomics and Diagnostics
(152)
Frequent Co-Authors
Affiliations
Supélec
Goethe University Frankfurt
University of Southern California
Roche (Switzerland)
Uppsala University